VERNON HILLS, Ill., Sept. 17 /PRNewswire-FirstCall/ -- Immtech International, Inc. announced today that representatives from the Company will be attending the BioJapan 2004 meeting in Tokyo, September 27 through September 30. BioJapan 2004 is Japan’s largest biotechnology conference. Information on Immtech will be available at the State of Illinois/Illinois Biotechnology Industry Organization (IBIO) Pavilion, which is part of the United States Pavilion.
If you would like more information on the BioJapan 2004 meeting, please connect to: http://biz.yahoo.com/prnews/040913/cgm051_1.html
About Immtech International
Immtech International, Inc. is a pharmaceutical company advancing the development and commercialization of oral drugs to treat infectious diseases and neoplastic (cancer) and metabolic (diabetes) disorders. We are developing treatments for fungal infections, malaria, tuberculosis, cancer, diabetes, Pneumocystis carinii pneumonia (“PCP”) and tropical diseases, including African sleeping sickness (trypanosomiasis) and leishmaniasis. We have a worldwide, exclusive license to commercialize a dicationic pharmaceutical platform from which a pipeline of products may be developed to target large, global markets.
“Safe Harbor” Statement under the Private Securities Reform Act of 1995: Statements in this press release regarding Immtech International, Inc.'s business which are not historical facts are “forward-looking statements” that involve risks and uncertainties. For a discussion of such risks and uncertainties that could cause actual results to differ from those contained in the forward-looking statements, see “Risk Factors” in the Company’s Annual Report on Form 10-K/A for the most recently ended fiscal year.
Immtech International, Inc.
CONTACT: F. C. Thompson, 1-877-898-8038, for Immtech International,Inc.
